Designed for accessibility — adjust text size or contrast at any time
Text
Back to Literature Hub
Clinical Research Update

Understanding the New Kidney Treatment: A Simple Guide to the ACHIEVE Trial.

Dr. Roger N. Smith, FACP Published: June 2026

If you or a loved one are living with kidney disease, you know how stressful it can be to hear about declining kidney function, urine tests, and the future risk of dialysis.

Recently, a major medical study called the ACHIEVE Trial was published in The Lancet and presented at the European Renal Association (ERA) 2025 congress. Let's break down exactly what this study found, without all the confusing medical jargon.

Study Source Reference

The ACHIEVE Trial (Assessment of Clinical Health Outcomes in Patients with End-stage Renal Disease on Hemodialysis). Published in The Lancet / Presented at the 62nd ERA Congress, 2025.

What Was This Study Testing?

Researchers wanted to see if a widely used medicine - a mineralocorticoid receptor antagonist (aldosterone blocker) - could protect the hearts and residual kidney function of people undergoing maintenance dialysis.

  • Who participated? Adult patients with end-stage kidney disease undergoing maintenance hemodialysis for at least 3 months.
  • What did they do?Half of the patients took the medicine, while the other half took a “placebo” (a harmless dummy pill) so researchers could accurately compare the outcomes between the two groups.

The Big Discovery 🎉

The results of the trial were incredibly encouraging! Patients who received the active medicine experienced:

📉
Urine Protein Reduction
A huge reduction in protein leaking into the urine (albuminuria), which is a major clinical sign of kidney stress.
🛡️
eGFR Preservation
Better preservation of overall residual kidney strength (measured via eGFR) over the course of the study.

What Does This Mean For You?

This represents a massive step forward. For years, doctors had very few tools to treat and protect residual function in this specific patient cohort. Now, we have high-quality clinical evidence for a targeted medicine designed to help slow down damage and protect your cardiovascular and renal systems.

Questions to ask your kidney doctor at your next visit:

  1. “Am I a good candidate for the treatment tested in the ACHIEVE Trial study?”
  2. “What are the common side effects (such as potassium levels) I should watch out for?”
  3. “Will this help slow down my kidney damage so I can delay dialysis or protect my remaining function?”

Need Professional Advice?

Dr. Roger Smith and the team at Renal Services Limited offer specialized consultations, including clinical reviews of new therapies, at our offices in Jamaica.

Meridian Medical Specialists
Unit 9, 2 Phoenix Avenue, Kingston 10
Call (876) 634-5142
The Dialysis Centre (Mandeville)
Shop 12 2 leadrs plaza
Call (876) 961-1693

Medical Disclaimer: This article is written for general patient education purposes and is based on published clinical trials. It is not a substitute for personalised medical advice. All treatment decisions should be made in consultation with your own physician.

Sources: Assessment of a Mineralocorticoid Receptor Antagonist in Patients with ESKD Undergoing maintenance hemodialysis: results from the ACHIEVE Trial. Presented at the ERA Congress 2025.